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Summary
Background People who inject drugs (PWID) are at increased risk for HIV and hepatitis C virus (HCV) infection and 
also have high levels of homelessness and unstable housing. We assessed whether homelessness or unstable housing 
is associated with an increased risk of HIV or HCV acquisition among PWID compared with PWID who are not 
homeless or are stably housed.
Methods In this systematic review and meta-analysis, we updated an existing database of HIV and HCV incidence 
studies published between Jan 1, 2000, and June 13, 2017. Using the same strategy as for this existing database, we 
searched MEDLINE, Embase, and PsycINFO for studies, including conference abstracts, published between 
June 13, 2017, and Sept 14, 2020, that estimated HIV or HCV incidence, or both, among community-recruited PWID. 
We only included studies reporting original results without restrictions to study design or language. We contacted 
authors of studies that reported HIV or HCV incidence, or both, but did not report on an association with homelessness 
or unstable housing, to request crude data and, where possible, adjusted effect estimates. We extracted effect estimates 
and pooled data using random-effects meta-analyses to quantify the associations between recent (current or within the 
past year) homelessness or unstable housing compared with not recent homelessness or unstable housing, and risk of 
HIV or HCV acquisition. We assessed risk of bias using the Newcastle-Ottawa Scale and between-study heterogeneity 
using the I² statistic and p value for heterogeneity.
Findings We identified 14 351 references in our database search, of which 392 were subjected to full-text review 
alongside 277 studies from our existing database. Of these studies, 55 studies met inclusion criteria. We contacted the 
authors of 227 studies that reported HIV or HCV incidence in PWID but did not report association with the exposure 
of interest and obtained 48 unpublished estimates from 21 studies. After removal of duplicate data, we included 
37 studies with 70 estimates (26 for HIV; 44 for HCV). Studies originated from 16 countries including in North America, 
Europe, Australia, east Africa, and Asia. Pooling unadjusted estimates, recent homelessness or unstable housing was 
associated with an increased risk of acquiring HIV (crude relative risk [cRR] 1·55 [95% CI 1⋅23–1·95; p=0·0002]; 
I² = 62⋅7%; n=17) and HCV (1⋅65 [1·44–1⋅90; p<0·0001]; I² = 44⋅8%; n=28]) among PWID compared with those who 
were not homeless or were stably housed. Associations for both HIV and HCV persisted when pooling adjusted 
estimates (adjusted relative risk for HIV: 1·39 [95% CI 1⋅06–1⋅84; p=0·019]; I² = 65·5%; n=9; and for HCV: 1⋅64 
[1⋅43–1⋅89; p<0⋅0001]; I² = 9·6%; n=14). For risk of HIV acquisition, the association for unstable housing (cRR 1⋅82 
[1⋅13–2⋅95; p=0⋅014]; n=5) was higher than for homelessness (1⋅44 [1⋅13–1⋅83; p=0⋅0036]; n=12), whereas no 
difference was seen between these outcomes for risk of HCV acquisition (1⋅72 [1⋅48–1⋅99; p<0·0001] for unstable 
housing, 1⋅66 [1⋅37–2⋅00; p<0⋅0001] for homelessness).
Interpretation Homelessness and unstable housing are associated with increased risk of HIV and HCV acquisition 
among PWID. Our findings support the development of interventions that simultaneously address homelessness 
and unstable housing and HIV and HCV transmission in this population.
Funding National Institute for Health Research, National Institute on Drug Abuse, National Institute of Allergy and 
Infectious Diseases, and Commonwealth Scholarship Commission. 
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Globally, HIV and viral hepatitis are leading causes of 
mortality,1,2 with people who inject drugs (PWID) being 
highly susceptible to HIV and hepatitis C virus (HCV) 
infection.3–6 Over 2018–30, an estimated 43% of global 
HCV transmission is projected to be attributed to 
unsafe injecting practices among PWID.6 Approximately 
8% of new HIV infections globally and 20% outside 
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sub-Saharan Africa occur among PWID.5 Although 
effective prevention and treatment interventions exist for 
reducing the transmission of HIV and HCV among 
PWID,7–11 coverage remains low globally.12 Addi tionally, 
PWID are usually exposed to multiple adverse environ-
ments (eg, incarceration and homelessness) that can 
increase their risk of HIV and HCV infec tion.13–16 Home-
lessness, defined by the Institute of Global Homelessness 
as lacking access to adequate housing, and unstable 
housing, typically defined as being without fixed housing, 
are widely acknowledged as important risk factors for 
acquisition of HCV or HIV infection,13–16 and have been 
implicated in a series of HIV outbreaks among PWID over 
the past 10 years.17
Homelessness or unstable housing is a well established 
determinant of poor health outcomes and excess mor-
tality,18–21 affecting many PWID. Globally, an estimated 22% 
of PWID report experiencing homelessness or unstable 
housing in the past year.4 Relative to PWID living in stable 
housing, those who are homeless or unstably housed are 
more likely to engage in high-risk behaviours associated 
with HIV and HCV transmission, such as sex work, public 
injecting, and sharing of injec tion equipment.22–24 They 
also experience barriers to accessing drug addiction 
treatment25,26 and HIV and HCV prevention and care.23,27,28 
Studies exploring the percep tions of PWID around high-
risk behaviours for HCV infection have further highlighted 
the detrimental effect of homelessness.29
Research in context
Evidence before this study
We searched PubMed, with no language restrictions, 
for publications since database inception up to July 9, 2020, 
using the terms (“HIV” OR “hepatitis C” OR “HCV”) AND 
(“homelessness” OR “unstable housing”) AND (“inject drugs” 
OR “injecting drug” OR “substance abuse” OR 
“intravenous/epidemiology [MeSH] ” OR “substance-related 
disorders/epidemiology [MeSH]”). We identified studies that 
suggested that recent homelessness or unstable housing was 
negatively associated with initiation and adherence to opioid 
substitution treatment (OST; eight studies), use of 
needle-syringe programmes (two studies), initiation and 
adherence to HIV and hepatitis C virus (HCV) treatment and 
their outcomes (20 studies), cessation of injecting drug use 
(three studies), and access to primary care (one study). 
Conversely, recent homelessness or unstable housing was 
positively associated with prevalent HIV and HCV infection 
(18 studies), stimulant injecting (ten studies), increased 
injecting frequency (six studies), increased duration of injecting 
(one study), exposure to physical and sexual violence 
(nine studies), use of emergency services and admission to 
hospital (six studies), overdose (three studies), and mortality 
(three studies). Our search also identified studies that reported 
a positive association between homelessness or unstable 
housing and unemployment (two studies), food insecurity 
(one study), incarceration (three studies), high-risk sexual 
behaviours such as commercial sex (15 studies), and high-risk 
injecting practices such as receptive syringe sharing and public 
injecting (27 studies). We identified a systematic review on 
factors associated with injecting-related risk behaviours among 
people who inject drugs (PWID) that implicated homelessness 
and unstable housing as important determinants of risky 
injecting practices, such as increased injecting frequency, public 
injecting, syringe sharing, and stimulant injecting. Additionally, 
we found a systematic review of factors associated with HIV 
treatment adherence among PWID, which identified 
homelessness or unstable housing as a substantial structural 
barrier to adherence. We also found several studies linking 
homelessness or unstable housing with incident HIV and HCV 
infection or reinfection among PWID (21 studies). We also 
identified a study in which PWID who experienced increased 
housing stability over time had lower injecting frequency than 
those with decreasing housing stability. Furthermore, 
we identified a systematic review of outcomes associated with 
participation in Housing First programmes, which suggests that 
housing interventions are associated with reduced high-risk 
sexual behaviours and improved treatment outcomes among 
homeless populations with HIV.
Added value of this study
To our knowledge, this is the first systematic review and 
meta-analysis on the effect of recent homelessness or unstable 
housing on risk of HIV and HCV acquisition among PWID 
compared with PWID who are not homeless or who are stably 
housed. Our study also builds on previously published evidence 
through collating and pooling unpublished estimates, obtained 
by contacting authors of all identified studies of PWID that 
reported a measure of HIV or HCV incidence but not on our 
outcomes of interest. This resulted in an additional 21 studies 
being included in our review, nearly tripling the overall number 
of estimates included. We found that recent homelessness or 
unstable housing (current, or past 1–12 months) was associated 
with an increased risk of HIV and HCV acquisition and these 
associations mostly persisted in sensitivity analyses.
Implications of all the available evidence
Our review supports increasing evidence on the deleterious 
effect of housing instability on the health and social outcomes 
of PWID, specifically increased risk of HIV and HCV acquisition. 
Homeless and unstably housed PWID often face profound 
disadvantages and have multiple competing priorities. 
Therefore, a comprehensive approach that not only provides 
housing but also addresses many of the interlinked health and 
social concerns of this population is necessary to reduce HIV 
and HCV risk. Further research is needed to better understand 
how homelessness and unstable housing increases the risk of 
HIV and HCV acquisition, and what interventions could most 
effectively reduce this risk. This research would guide policies to 
help PWID attain and maintain housing stability.
Articles
www.thelancet.com/public-health   Vol 6   May 2021 e311
Although multiple studies have reported associations 
between homelessness or unstable housing and incident 
HIV and HCV infection among PWID,30–34 to date, no 
syste matic review has synthesised these data. We did a 
systematic review and meta-analysis to quantify the 
associ ations between homelessness or unstable housing 
and the risk of HIV and HCV acquisition among PWID.
Methods
Search strategy and selection criteria
In this systematic review and meta-analysis, we updated 
an existing database of HIV and HCV incidence studies 
published between Jan 1, 2000, and June 13, 2017. This 
reference database was compiled during a previous syste-
matic review and meta-analysis.35 Using the same strategy 
developed previously,35 CA did a systematic literature 
search of MEDLINE, Embase, and PsycINFO for studies 
published between June 13, 2017, and Sept 14, 2020, 
including conference abstracts, without language restric-
tions. We used terms related to HIV infection, HCV 
infection, injecting drug use, and study designs that could 
be used to estimate incidence of HIV or HCV (a full list of 
search terms is in the appendix [pp 7–8]). We restricted our 
analysis to studies done among community-recruited (ie, 
not recruited in prisons) PWID (those with history of 
recent or ever injecting drug use) that assessed HIV or 
HCV incidence. We included studies if they had already 
assessed or were able to assess whether or not an associ-
ation existed between recent homelessness or unstable 
housing and HIV or HCV incidence compared with PWID 
who were not recently homeless or were stably housed. We 
allowed for study-level differences in the definition of 
homelessness and unstable housing, and the timeframe 
definition of recent, which varied from currently to the 
past 1–12 months. We included studies that measured HIV 
or HCV incidence through longitudinal follow-up and 
testing or biological markers of recent infection (eg, anti-
HCV avidity and BED assays for HCV and HIV).33,36 We 
only included studies reporting original results without 
restric tions to design or language. We contacted authors of 
studies (including those published as conference abstracts) 
that reported estimates of HIV and HCV incidence, but 
did not report on the association with homelessness or 
unstable housing, to request data. We also contacted 
the lead investigators of other ongoing HIV and HCV 
incidence cohorts to request data. We requested crude and, 
where possible, adjusted effect estimates (preferably in the 
form of hazard ratios [HRs] and adjusting for opioid 
substitution therapy [OST] exposure, recent incarceration, 
and stimulant injecting), as done previously.7,8,35 Through-
out this Article, we use the term unpublished estimates 
to refer to estimates that we calculated for this study 
from raw data obtained by contacting authors. Although 
these estimates of associations between home lessness or 
unstable housing and HIV or HCV acquisition had not 
been previously presented, the vast majority were calcu-
lated using raw data from studies with published estimates 
of HIV or HCV incidence. For these unpublished 
estimates, we cite the most recently published article that 
was based on the same cohort. Some of the cohorts 
included in this systematic review and meta-analysis 
extend over long periods of time. Estimates derived from 
the same cohort but based on different durations of follow-
up were identified on the basis of matching study names, 
settings, or authors, or a combination of these. To avoid 
publication bias, we included only one esti mate, retaining 
the one with the most person-years of follow-up overall.
We created an Endnote library (version X9) to catalogue 
the search results and to de-duplicate references. After 
See Online for appendix
Figure 1: Study selection
Unpublished estimates are those that have been calculated from raw data for this study and have not been 
presented in previously published studies. HCV=hepatitis C virus. PWID=people who inject drugs.





8585 studies identified for title and 
abstract screening
669 eligible for full-text screening
5766 duplicates removed
39 studies with 57 published estimates excluded 
because they were duplicate data 
8193 excluded
277 HIV and HCV incidence studies from 
existing literature database
614 excluded
303 did not report incidence estimate
227 did not report outcome of interest
6 done outside of community setting
29 did not report original results
48 did not report HIV or HCV incidence in PWID
1 estimated incidence by self-report
166 individuals contacted (either authors of studies   
         that did not report outcome of interest or known 
         to be leading ongoing HIV or HCV incidence 
         cohort studies)
21 studies with 48 unpublished estimates55 relevant studies with 79 published estimates 
21 studies with 48 unpublished estimates included in 
the final analysis
12 studies with 18 estimates for HIV incidence
17 studies with 30 estimates for HCV incidence
16 studies with 22 published estimates included in 
the final analysis
5 studies with 8 estimates for HIV incidence
11 studies with 14 estimates for HCV incidence
76 studies, with 127 estimates (published and unpublished)
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removal of duplicates, CA screened the titles and abstracts 
of the studies to identify papers or reports that might 
contain relevant information. After finding discrepancies 
during an initial double-screening of a random 10% of 
studies, HF, JS, SB, AT, JGW, AGL, LM, JJO, and ZW 
double-screened all the titles and abstracts, with disagree-
ments resolved by group discussion. CA screened the full 
texts of potentially relevant records to identify those that 
met the inclusion criteria. HF, JS, SB, AT, JGW, AGL, LM, 
JJO, and ZW double-screened these records with dis-
crepancies resolved by group discussion. We used Google 
Translate to read non-English language papers.
This study is reported in accordance with PRISMA 
guidelines37 (appendix pp 1–2). Details of the methods were 
prespecified and documented in a protocol (appendix 
pp 3–6). No deviations from the protocol occurred.
Data analysis
We sought unadjusted and adjusted summary esti-
mates for our main analysis, as well as summaries of 
participant-level and study-level characteristics for our 
subgroup analyses, meta-regression, and sensitivity analy-
ses. CA extracted data from selected studies into Microsoft 
Excel using a pre-defined data extraction spreadsheet 
(appendix p 8). JS, HF, and AAA double-checked the 
extracted data, with discrepancies resolved by group 
discussion. We extracted one unadjusted and adjusted 
effect measure from pub lished papers, prioritising HRs, 
incidence rate ratios, and relative risks (RRs) over odds 
ratios (ORs). When an effect estimate was not reported, 
we calculated one from the available data. Consistent with 
previously published methods,38 we transformed ORs 
and their 95% CIs into RRs when incidence was high 
(>10 per 100 person-years).
We assessed the risk of bias for each estimate of HIV 
or HCV incidence for each study using the Newcastle-
Ottawa Scale.39 The scale allocates a maximum of 9 points 
indicating a low risk of bias depending on the selection of 
study participants, comparability of participants, and 
ascertainment of the outcome. To assess the comparability 
of participants, we examined whether the reported effect 
estimates were adjusted for three variables that we 
identified a priori as being potentially confound ing 
factors: OST exposure, history of incarcera tion, and 
history of stimulant injecting. This decision was based on 
studies reporting a lower risk of HIV and HCV infection 
among PWID on OST,7,8 and an inverse association 
between homelessness or unstable housing and OST 
exposure.30,40 Conversely, some studies have indicated that 
PWID who have been recently incarcerated or who inject 
stimulants have a greater risk of HIV and HCV infection41,42 
and are more likely to be homeless or unstably housed.23,43,44 
We gave 1 point to studies that adjusted for OST exposure 
and 1 point to those that adjusted for history of incar-
ceration or stimulant injecting, or both. To assess the risk 
of bias in unpublished estimates, we consulted the 
corresponding published paper or papers. For all records, 
risk of bias was independently assessed by two authors 
(CA and JS or HF) with discrepancies resolved by 
discussion with AAA.
We combined study-specific effect estimates using 
random-effects meta-analysis, because we anticipated 
high between-study variation. We log-transformed effect 
measures and their SEs, with crude and adjusted estimates 
pooled separately. We plotted the unadjusted estimates 
onto a forest plot and assessed heterogeneity by inspec-
tion of these plots, and using the I² statistic and p value for 
heterogeneity.45
We did separate sensitivity analyses to assess the 
robustness of pooled estimates by restricting the meta-
analysis to: studies that reported HRs (most common 
effect measure), studies at low-to-moderate risk of bias 
(Newcastle-Ottawa Scale score of ≥6), longitudinal studies, 
adjusted estimates, and studies in which 90% or more of 
partici pants had injected recently. The confounding 
factors included in the adjusted analyses varied between 





p value I² pheterogeneity
Effect on risk of HIV acquisition
Unadjusted effect estimates 17 1·55 (1·23–1·95) 0·0002 62·7 0·0003
Adjusted effect estimates 9 1·39 (1·06–1·84) 0·019 65·5 0·0031
Published unadjusted estimates 5 1·65 (1·11–2·44) 0·012 77·3 0·0015
Unpublished unadjusted 
estimates*
12 1·46 (1·12–1·91) 0·0048 42·7 0·058
Only longitudinal studies 15 1·62 (1·27–2·07) 0·0001 63·4 0·0005
Only studies with hazard ratios 10 1·56 (1·08–2·25) 0·018 73·5 <0·0001
Only studies with at least 90% of 
participants injecting recently
11 1·44 (0·97–2·13) 0·068 75·4 0·0001
Only studies at low-to-moderate 
risk of bias
10 1·56 (1·14–2·12) 0·0052 72·6 0·0001
Estimate for homelessness 12 1·44 (1·13–1·83) 0·0036 52·7 0·016
Estimate for unstable housing 5 1·82 (1·13–2·95) 0·014 67·8 0·014
Effect on risk of HCV acquisition†
Unadjusted effect estimates 28 1·65 (1·44–1·89) <0·0001 44·8 0·0060
Adjusted effect estimates 14 1·64 (1·43–1·89) <0·0001 9·6 0·35
Published unadjusted estimates 11 1·61 (1·18–2·19) 0·0029 66·9 0·0008
Unpublished unadjusted estimates* 17 1·69 (1·49–1·92) <0·0001 14·2 0·29
Only longitudinal studies 25 1·61 (1·40–1·86) <0·0001 38·6 0·027
Only studies with hazard ratios 18 1·59 (1·36–1·86) <0·0001 45·6 0·019
Only studies with at least 90% of 
participants injecting recently
20 1·54 (1·32–1·80) <0·0001 39·0 0·039
Only studies at low-to-moderate 
risk of bias
19 1·67 (1·37–2·03) <0·0001 52·4 0·0042
Estimate for homelessness 19 1·66 (1·37–2·00) <0·0001 55·3 0·0018
Estimate for unstable housing 10 1·72 (1·48–1·99) <0·0001 0·0 0·47
HCV=hepatitis C virus. PWID=people who inject drugs. *Unpublished estimates are those that have been calculated from 
raw data for the current study and have not been presented in previously published papers. †One study (unpublished 
estimate, provided by Wijnand and colleagues) provided estimates for both unstable housing and homelessness. For all 
sensitivity analyses, the effect of unstable housing from this study was used, except when pooling estimates specifically 
for homelessness or unstable housing. Hence, the number of studies for these two sensitivity analyses add up to 29.
Table 2: Sensitivity analysis of the effect of recent homelessness or unstable housing on risk of HIV or 
HCV acquisition in PWID compared with PWID who are not homeless or are stably housed
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plot asymmetry to assess the risk of bias due to missing 
results for each outcome.
We did subgroup and random-effects meta-regression 
analyses to investigate potential sources of heterogeneity, 
as prespecified in the protocol (appendix p 5). These 
potential sources of heterogeneity included the baseline 
characteristics of participants (proportion female, propor-
tion ever incarcerated, proportion recently incarcerated, 
proportion prescribed OST, mean or median age, time 
since starting injecting drug use, and HIV or HCV pre-
valence), study characteristics (publication status, study 
design, years of study, study duration, effect measure, 
timeframe for defining recent homelessness or unstable 
housing), and geographical and economic region.
We did all analyses separately for HIV and HCV. We did 
all data analysis using Stata (version 15.1).
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or writing 
of the report.
Results
Through our database searches of HIV and HCV incidence 
studies published between June 13, 2017, and Sept 14, 2020, 
we identified 14 351 potentially eligible studies, of which 
5766 were duplicates (figure 1). Initial screening of titles 
and abstracts of the remaining 8585 studies resulted in 
392 studies eligible for full-text review. We retrieved 
277 additional studies from our existing database of HIV 
and HCV incidence studies (search from Jan 1, 2000, to 
June 13, 2017),35 which resulted in 669 references for full-
text review. Of these, 55 studies (79 estimates) met the 
inclusion criteria. Additionally, we identified 227 studies 
that measured HIV or HCV incidence among PWID but 
did not report an association with the exposure of interest. 
We contacted the authors of these studies and known lead 
investigators of other ongoing HIV and HCV incidence 
cohorts to request data. 48 unpublished estimates (from 
21 studies) were obtained from these sources; 43 were 
from published studies reporting HIV and HCV inci-
dences, but not reporting the exposure of interest, four 
were updates of previously published estimates, and one 
was from an ongoing study that had not yet been published. 
Overall, we identified 76 studies with 127 estimates 
that met the inclusion criteria for our review. Of these, 
we excluded 39 studies with 57 estimates as duplicate 
data (details of excluded studies are shown in the 
appendix [pp 9–10]).
The characteristics of studies included in the final 
analysis are shown in table 1, which includes 37 studies, of 
which eight reported data for both HIV and HCV 
incidence, originating from 16 countries, giving 70 effect 
estimates (22 published and 48 unpublished estimates) 
done between 1986 and 2020. There were 29 314 participants 
across HIV studies and 21 842 participants across HCV 
studies. There were 32 longitudinal studies (15 for HIV; 
25 for HCV) and five cross-sectional studies (two for HIV; 
three for HCV); total person-years of follow-up for HIV 
longitudinal studies was 51 977 person-years (data missing 
for three studies) and for HCV longitudinal studies was 
22 370 person-years (data missing for four studies). Of 
included effect estimates, 49 measured the effect of recent 
homelessness (19 for HIV; 30 for HCV), while 21 measured 
the effect of recent unstable housing (seven for HIV; 14 for 
HCV), with the timeframe for recent defined as currently 
for 12 studies, 6 months or less for 19 studies, and less 
than 12 months for six studies. Although not all included 
studies provided an explicit definition for homelessness 
or unstable housing, homelessness was generally defined 
as living on the streets, in cars, and in abandoned 
houses,41,67,69,75 whereas unstable housing was defined as 
being without fixed housing,75 including so-called sofa-
surfing and living on the street, in hostels, in guesthouses, 
in shelters, in single-room occupancies, or in short-term 
rentals (typically motels, hotels, rooming or multitenant 
houses, or rented rooms).47,48,68,75 These definitions were not 
mutually exclusive, such that unstable housing often 
incorporated homelessness. The overall proportion of 
female participants was 4127 (15·6%) of 26 384 participants 
for HIV studies (data missing for two studies) and 
5332 (28·6%) of 18 628 for HCV studies (data missing for 
Figure 2: Meta-analysis of studies showing the unadjusted effect of recent homelessness or unstable housing 
on risk of HIV acquisition in PWID compared with PWID who are not homeless or are stable housed, by 
publication status
For unpublished estimate studies, we listed the studies by the principal investigator who supplied the data and 
referenced the most recently published article that was based on the same cohort. Unpublished estimates are those 
that have been calculated from raw data for this study and have not been presented in previously 
published studies. PWID=people who inject drugs.
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five studies). We saw large differ ences in baseline 
prevalence of HIV (0⋅0–43⋅6%) and HCV (11⋅5–85·0%). 
In total, there were 1224 incident HIV infections (data 
missing for two studies), with HIV incidence ranging 
from 0⋅9–20·0 per 100 person-years, and 1051 incident 
HCV infections (data missing for three studies), with 
HCV incidence ranging from 0⋅9–64·5 per 100 person-
years. Further details on study character istics are in the 
appendix (pp 20–28).
17 studies provided 26 estimates (of which 18 were 
unpublished estimates) for the association between recent 
homelessness or unstable housing and risk of HIV 
acquisition. 17 estimates were unadjusted estimates and 
nine were adjusted estimates (table 1). In the unadjusted 
analysis, compared with PWID who were not recently 
homeless or were stably housed, recent homelessness 
or unstable housing was associated with a crude RR (cRR) 
for HIV acquisition of 1·55 (95% CI 1⋅23–1⋅95; p=0⋅0002) 
with substantial between-study heterogeneity (I² = 62·7%; 
p=0⋅0003; table 2; figure 2). In the sensitivity analyses, the 
pooled unadjusted estimate from published estimates was 
similar (cRR 1⋅65 [95% CI 1⋅11–2·44]; p=0⋅012) to the 
pooled unadjusted estimate of those calculated from raw 
data (1·46 [1·12–1·91]; p=0·0048; table 2; figure 2). The 
risk was reduced slightly when adjusted estimates were 
pooled (adjusted RR 1·39 [1·06–1·84]; p=0·019). The 
direction of association was consistent and similar in all 
other sensi tivity analyses, except when considering the 
association between recent unstable housing and risk of 
HIV acquisition, for which the effect size was larger 
(cRR 1·82 [1·13–2·95]; p=0·014; table 2). Additionally, 
when pooling studies with at least 90% of participants 
with recent injecting the association was no longer 
significant. In the subgroup and meta-regression analyses, 
we found no evidence that the effect of recent home-
lessness or unstable housing on HIV acquisition risk 
differed by region, baseline characteristics of study 
participants, or study characteristics (appendix pp 11–12).
28 studies provided 44 estimates (of which 30 were 
unpublished) of the association between homelessness 
or unstable housing and risk of HCV acquisition. One 
study (unpublished estimate, provided by Wijnand and 
colleagues; table 1) provided unadjusted and adjusted effect 
estimates for both homelessness and unstable housing, 
with the definition of unstable housing encom pas sing 
homelessness. For all analyses, we used the estimate for 
unstable housing, except for the sensitivity analysis where 
effect estimates for homelessness and unstable housing 
were pooled separately. Therefore, in the main analyses, we 
included 28 unadjusted and 14 adjusted estimates (table 1). 
In the unadjusted analysis, compared with PWID who 
were not homeless or were stably housed, recent home-
lessness or unstable housing was associated with a cRR for 
HCV acquisition of 1·65 (95% CI 1·44–1·89; p<0·0001) 
with moderate between-study heterogeneity (I² = 44·8%, 
p=0·0060; table 2; figure 3). In sensitivity analyses, the 
pooled unadjusted estimate from published estimates was 
similar (cRR 1·61 [1·18–2·19; p=0·0029) to the pooled 
unadjusted estimate of those calculated from raw data 
(1·69 [1·49–1·92]; p<0·0001; table 2; figure 3). The risk was 
similar when adjusted estimates were pooled (adjusted 
RR 1·64 [1·43–1·89]; p<0·0001; table 2). The association 
was similar across all other sensitivity analyses (table 2). 
The subgroup and meta-regression analyses suggest that 
the association between recent homelessness or unstable 
housing and HCV acquisition risk was higher in studies 
done in Europe than elsewhere (North America, 
Australasia, and south and central Asia), higher in studies 
with greater baseline OST coverage, and higher in studies 
spanning longer time periods (appendix pp 12–14).
We found no evidence of asymmetry in funnel plots for 
either of the two summary measures by visual inspection or 
Figure 3: Meta-analysis of studies showing unadjusted effect of recent homelessness or unstable housing on 
risk of HCV acquisition in PWID compared with PWID who are not homeless or are stably housed, by 
publication status
For unpublished estimate studies, we listed the studies by the principal investigator who supplied the data and 
referenced the most recently published article that was based on the same cohort. Unpublished estimates are 
those that have been calculated from raw data for this study and have not been presented in previously published 
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Egger’s test (p=0·51 for both HIV and HCV; appendix 
pp 16–17). Overall, the risk of bias score based on the 
Newcastle-Ottawa Scale varied from 4 points (three studies) 
to 9 points (two studies), and the median score did not 
differ for estimates of HIV and HCV studies, both being 6, 
indicating a low-to-moderate risk of bias (table 1; appendix 
pp 29–31). 
Discussion
We found strong evidence of an increased risk of HIV and 
HCV acquisition among PWID who are exposed to recent 
homelessness or unstable housing compared with PWID 
who are not homeless or are stably housed. Across all 
included studies, recent homelessness or unstable housing 
was associated with a 1·55 times greater risk of HIV 
acquisi tion and a 1·65 times greater risk of HCV acquisi-
tion. Although our estimates remained largely consistent 
in most sensitivity analyses, the pooled adjusted estimates 
indicated a slightly lower effect for HIV (RR 1·39) but not 
HCV (RR 1·64).
The association between recent homelessness or 
unstable housing and risk of HIV acquisition did not vary 
according to any of the factors considered, including 
participant and study characteristics and geographical or 
economic region. Conversely, the association with risk of 
HCV acquisition was greater in studies done in Europe, 
studies done in regions of higher OST coverage, and 
in longer studies. The reasons for these associations 
are unclear. Possibly, compared with North America and 
Australasia, PWID who are homeless or unstably housed 
in Europe are less likely to attend harm-reduction services, 
and thus are more likely to engage in high-risk behaviours. 
Alternatively, the definition of homelessness or unstable 
housing adopted in studies done in Europe might have 
been more likely to capture those at higher risk of HCV 
infection than studies done outside of Europe. Overall, 
although our findings could reflect true differ ences, they 
should be interpreted with caution. Some covariates had 
many missing values because they were not systematically 
reported in all studies, leading to sparse data across 
some categories. Also, some differences might be due to 
confounding, at least partly, given that the high number of 
missing values precluded multivariable meta-regression 
analyses.
Our finding of greater risk of HIV and HCV infection 
among PWID who experience housing instability than 
among PWID who are not homeless or who are stably 
housed can be attributed to increased injection and high-
risk sexual behaviours in this population, as previously 
reported.22,23,44,78,79 These behav iours are probably the result 
of broader health and social factors and difficult socio-
economic circum stances experi enced by homeless and 
unstably housed PWID, including inadequate access to 
harm-reduction services,25,26,30,40,80 mental health disorders,44 
incarcera tion,23,24,44 unemploy ment,44 and food insecurity.81 
Over all, our findings align with the syndemic framework 
for conceptualising health outcomes, which suggests 
that over lapping biosocial problems do more than just 
cluster together but exacerbate health inequalities.82 Both 
homeless ness and drug dependence carry stigma, dis-
crimination, and structural inequalities, and together can 
amplify susceptibility to adverse health outcomes. For 
example, in studies exploring the perceptions of homeless 
PWID, the stress surrounding their precarious living 
circumstances and the pervasiveness of drugs in the social 
environment were found to considerably amplify drug use 
and high-risk behaviours.79,83,84
Housing First85–87 is one initiative that aims to reduce 
homelessness that has been adopted in some high-income 
countries. This model centres on providing immediate 
housing to marginalised populations, and is not con-
tingent on them being enrolled into drug treatment 
services or ceasing drug use. Additional support for those 
with mental health and substance use disorders is also 
offered. Although the effectiveness of this initiative on 
HIV and HCV transmission and injecting-related risk 
behaviours has yet to be determined, it has been shown to 
have a positive impact on mental health and substance 
use, social integration, housing stability, quality of life, 
and involvement with the criminal justice system.87,88 Other 
housing interventions can also reduce high-risk sexual 
behaviours and improve treatment outcomes among 
homeless popu lations living with HIV,89 but few studies 
have considered homeless PWID.
Despite evidence of their benefit, housing initiatives are 
not well established in most high-income countries,87 and 
even less so in low-income and middle-income coun-
tries. However, during the ongoing COVID-19 pandemic, 
numerous countries (including the UK, France, Australia, 
and the USA) rapidly escalated their efforts to provide safe 
and secure housing to homeless or unstably housed 
individuals.90–92 In England, UK, these efforts have not 
only potentially reduced COVID-19 outbreaks in this 
group,93 but has also resulted in increased linkage to care 
with opportunities to address long-standing health issues, 
such as testing and treatment for tuberculosis, HIV, and 
HCV.94 Comprehensive efforts like these that provide 
housing alongside harm-reduction programmes and 
access to HIV and HCV treatment for those who are 
infected are needed to achieve meaningful reductions in 
transmission. Expanding access to treatment among 
homeless PWID should be prioritised given the unique 
barriers faced by this group,95,96 despite the availability of 
effective and cost-effective HIV and HCV testing and 
treatment interventions.97–99
A strength of our study is that it includes 48 unpublished 
estimates, increasing the number of included estimates 
from 22 to 70, so minimising the risk of publication bias. 
Nonetheless, our study had several limitations. First, 
because our review involved observational studies, we 
cannot rule out unmeasured confounding. Although our 
estimates remained consistent after adjustment for OST 
exposure, history of incarceration, and stimulant injecting, 
and we found a low-to-moderate risk of bias across studies, 
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other factors might have confounded the association 
(eg, ethnicity, severity of addiction, or mental health 
disorders, which are rarely measured in these studies). 
Second, selection bias is another limitation of longitudinal 
observational studies because PWID who are homeless 
or unstably housed might have increased attrition. If 
participants who were lost to follow-up had a higher risk of 
acquisition than those who remained in follow-up, we 
might have underestimated the true associations between 
homelessness or unstable housing and risk of HIV and 
HCV acquisition. Importantly, we assessed selection bias 
using the Newcastle-Ottawa Scale and our estimates 
remained consistent when pooling studies at low-to-
moderate risk of bias. Third, differences across studies in 
the measurement of homelessness and unstable housing 
could have introduced bias in the pooled estimates. Our 
sensitivity and meta-regression analyses revealed some 
non-significant differences between estimates that defined 
exposure using different time frames (eg, past year vs past 
6 months or currently) or based on whether participants 
were homeless or unstably housed. Unfortunately, we did 
not have the statistical power to draw conclusions with 
regards to these differ ences. These limitations are likely to 
be amplified by the absence of a universal definition of 
homelessness or unstable housing that accounts for differ-
ences across sociocultural settings, making the monitoring 
of home lessness and its effect on health outcomes across 
different countries and regions difficult. We were also 
restricted in our ability to examine whether the association 
between homelessness and unstable housing and HIV or 
HCV risk varied as a function of other factors, such as 
coverage of needle and syringe provision or antiretroviral 
therapy. As mentioned, meta-regression analyses were 
underpowered to detect significant differ ences due to the 
high proportion of missing data. Fourth, data from low-
income and middle-income coun tries was scarce, with 
only nine studies being available from such settings for 
this systematic review and meta-analysis (seven HIV 
studies and two HCV studies). Further studies are needed 
from low-income and middle-income countries to enable 
us to draw more generalisable conclusions. Finally, 
although details of the methods were prespecified and 
documented in a protocol, we were unable to register our 
protocol as intended due to changes in the PROSPERO 
eligibility criteria during the conduct of our study.
In summary, our study provides strong evidence that 
current or recent homelessness and unstable housing is 
associated with increased risk of HIV and HCV acquisition 
among PWID. These findings frame housing instability 
as an important driver of HIV and HCV transmission 
among PWID and call for intensified efforts to assess and 
implement housing initiatives and targeted prevention 
services that are tailored to the needs of this marginalised 
population. To help PWID attain and maintain housing 
stability, integrated strategies that address their competing 
health and social concerns are urgently needed. Great 
changes, albeit only the temporary provision of housing, 
achieved during the COVID-19 pandemic have shown that 
such strategies are possible when there is sufficient 
political will.
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